Natriuretic peptide receptor 1 antibodies and methods of use
AssigneeNovartis AG
InventorsJohn Louis Diener, Lars Gadtke, Felix Hartlepp, Tiancen Hu, Kathrin Ladetzki-Baehs, Michael John Romanowski, Cesare Russo, Xenia Wezler, Xiaoling Xie
Life of this patent
Estimating the term…
Abstract
This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.
Claims12
An isolated nucleic acid or nucleic acids encoding the amino acid sequence of an anti-NPR1 antibody or antigen binding fragment, wherein the antibody or antigen binding fragment comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) selected from:
- (I)
- SEQ ID NO:
- 28 (HCDR1),
- SEQ ID NO:
- 119 (HCDR2),
- SEQ ID NO:
- 30 (HCDR3),
- SEQ ID NO:
- 41 (LCDR1),
- SEQ ID NO:
- 42 (LCDR2), and
- SEQ ID NO:
- 134 (LCDR3);
- (II)
- SEQ ID NO:
- 31 (HCDR1),
- SEQ ID NO:
- 119 (HCDR2),
- SEQ ID NO:
- 30 (HCDR3),
- SEQ ID NO:
- 41 (LCDR1),
- SEQ ID NO:
- 42 (LCDR2), and
- SEQ ID NO:
- 134 (LCDR3);
- (III)
- SEQ ID NO:
- 32 (HCDR1),
- SEQ ID NO:
- 120 (HCDR2),
- SEQ ID NO:
- 30 (HCDR3),
- SEQ ID NO:
- 44 (LCDR1),
- SEQ ID NO:
- 45 (LCDR2), and
- SEQ ID NO:
- 135 (LCDR3);
- or
- (IV)
- SEQ ID NO:
- 34 (HCDR1),
- SEQ ID NO:
- 121 (HCDR2),
- SEQ ID NO:
- 36 (HCDR3),
- SEQ ID NO:
- 47 (LCDR1),
- SEQ ID NO:
- 45 (LCDR2), and
- SEQ ID NO:
- 134 (LCDR3).
Dependencies are inferred from the claim text.